Guardant Health guided to substantial screening growth in 2026 for its Shield colorectal cancer screening test and disclosed an acquisition of early cancer detection startup MetaSight Diagnostics. Management projected 2026 screening revenue of $162–$174 million and volumes of 210,000–225,000 tests, citing FDA approval for Shield and partnerships including Quest Diagnostics. Guardant paid $59 million upfront with up to $90 million in contingent consideration to acquire MetaSight, adding multi‑cancer early detection capabilities. Executives framed the move as a push to scale screening revenue and pipeline breadth; commercial upside depends on guideline inclusion, payer decisions and integration into provider ordering workflows.